- Home
- LXRX vs CEVA Comparison
LXRX vs CEVA Comparison
Compare LXRX & CEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | CEVA |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.7M | 823.5M |
| IPO Year | 2000 | 2002 |
Fundamental Metrics
Financial Performance| Metric | LXRX | CEVA |
|---|---|---|
| Price | $1.60 | $29.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $4.55 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 2.6M | 529.2K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $49,803,000.00 | ★ $87,507,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $13.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.24 | 20.45 |
| 52 Week Low | $1.10 | $17.02 |
| 52 Week High | $2.68 | $51.60 |
Technical Indicators
Market Signals| Indicator | LXRX | CEVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 44.49 |
| Support Level | $1.50 | $29.77 |
| Resistance Level | $1.81 | $39.71 |
| Average True Range (ATR) | 0.07 | 1.45 |
| MACD | -0.00 | -0.66 |
| Stochastic Oscillator | 27.20 | 28.05 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CEVA CEVA Inc.
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived mainly from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems. The company operates in one reportable segment: the licensing of IP to semiconductor companies and electronic equipment manufacturers.